

### REMARKS

The present invention relates to novel isolated marrow stromal cells ("MSCs") for use in treatment of a central nervous system ("CNS") disease, disorder or condition. The invention discloses methods comprising administering isolated marrow stromal cells into the CNS of a human patient thereby effecting treatment of a disease, disorder or condition thereof. Moreover, the stromal cells may be cultured *in vitro*, genetically engineered to produce therapeutic compounds, and/or pre-differentiated prior to administration into the CNS.

Original claims 1-3 and 7-20, are pending in the application, and claims 4-6 have been cancelled previously. Claims 1-3 and 7-18 have been canceled herein such that only claims 19 and 20 are pending in the above-captioned application.

At page 11 of the Office Action dated November 26, 2001 (Paper No. 24), the Examiner stated that claims 19 and 20 are allowable. Accordingly, Applicants have canceled, without prejudice, the pending claims (*i.e.*, claims 1-3 and 7-18), which stood rejected. Accordingly, Applicants respectfully request prompt allowance of claims 19 and 20.


### Summary

Applicants respectfully submit that each of claims 19 and 20, is in condition for allowance. Allowance of each of these claims are respectfully requested at the earliest possible date.

Respectfully submitted,

**DARWIN J. PROCKOP ET AL.**

November 26, 2002  
(Date)

By:   
**RAQUEL M. ALVAREZ, PH.D., J.D.**  
Registration No. 45,807  
**MORGAN LEWIS & BOCKIUS, L.L.P.**  
1701 Market Street  
Philadelphia, PA 19103  
Telephone No.: 215-963-5000  
**Direct Telephone: 215-963-5403**  
Facsimile: 215-963-5299

RMA/prw

Enclosures: (Request for Continued Examination and fee associated therewith; Petition for 4 month extension of time and fee therefor)